×
About 50,582 results

Guidance for Industry: Levothyroxine Sodium Tablets — In Vivo Pharmacokinetic and Bioavailability Studies and In Vitro Dissolution Testing
https://www.fda.gov/media/71591/download
FDA

KALYDECO® (ivacaftor) - For Healthcare Professionals
https://www.kalydecohcp.com/

Helpful information for your patients. Get product information intended for healthcare professionals. Resources. About KALYDECO. Studies and Data.

CAROSPIR (spironolactone oral suspension)
https://www.carospir.com/

CaroSpir provides a stable and consistent treatment option for adult patients who have difficulty swallowing and are suffering from heart failure, edema caused by heart failure and cirrhosis, and hypertension. In clinical studies, other formulations of spironolactone have demonstrated significant ...

DISCOVISC® OPHTHALMIC VISCOSURGICAL DEVICE
https://www.myalcon.com/products/surgical/ovds/discovisc-performance.shtml

See studies that prove why DisCoVisc ® is the only OVD designed for an entire cataract surgery and how it compares to Healon ® OVD at myalcon.com.

COSAMIN DS CAPSULES
http://www.cosamin.com/cosamin-ds

Clinically proven to help promote joint comfort. The most researched glucosamine chondroitin joint supplement. Cosamin®DS is proven to be effective in U.S. published clinical studies on joint health. At the cellular level, the ingredients in Cosamin DS work together to block enzymes that break down cartilage. Revolutionizing the science of joint care, the unique combination of 1500 mg glucosami...

FABIOR® (tazarotene) FOAM
https://www.fabior.com/hcp/home/

Treat your patients' acne with the power of tazarotene1. In clinical studies of once-daily FABIOR Foam used as monotherapy, patients with moderate-to-severe acne saw a 56.1% reduction in total acne lesions at week 12. Learn more. Give your patients the only topical retinoid acne treatment available in a foam.

IXEMPRA® (ixabepilone) INJECTION
http://ixempra.com/hcp/

When to use non-taxane therapy for metastatic breast cancer. Think IXEMPRA® (ixabepilone) when resistance emerges in mBC. ... Defined resistance criteria used in IXEMPRA® (ixabepilone) registrational studies.

Jentadueto® XR (linagliptin and metformin hydrochloride extended-release) tablets
https://hcp.jentadueto.com/

The safety and efficacy of JENTADUETO and JENTADUETO XR have been established based on adequate and well-controlled studies of linagliptin and ...

AMPYRA (dalfampridine) | For Healthcare Professionals
https://ampyra-hcp.com/

Learn more about AMPYRA. See clinical studies, patient videos and available financial assistance options. See Important Safety Information (including seizures) and Prescribing Information.

CRESEMBA® (isavuconazonium sulfate)
https://www.cresemba.com/

Learn more about CRESEMBA® (isavuconazonium sulfate), an FDA?approved antifungal medication indicated for the treatment of invasive aspergillosis & mucormycosis in adults. Specimens for fungal culture and other relevant laboratory studies (including histopathology) to isolate and identify causative organism(s)

SORILUX® (calcipotriene) Foam
https://www.soriluxfoam.com/hcp/home/

For your patients with scalp psoriasis. In a Phase III clinical study of moderate–severity scalp psoriasis, significantly more patients treated with SORILUX Foam achieved treatment success compared with vehicle foam.1. Learn more. For your patients with body psoriasis. In two 8-week, Phase III studies, SORILUX Foam was ...

Similac Infant Formula Products
https://abbottnutrition.com/similac

Learn about Similac Pro-Advance™ and Similac Pro-Sensitive™ with 2’-FL HMO, our infant formula products and clinical studies on term infant nutrition

VARIBAR (barium sulfate)
https://imaging.bracco.com/us-en/products/fluoroscopy/varibar

VARIBAR® (barium sulfate) 40% is an oral contrast for modified barium swallow (MBS) studies. Find Important Safety Information.

XEOMIN® (incobotulinumtoxinA) INJECTION
https://www.xeominaesthetic.com/professionals/

Explore physician provider product information, clinical studies and their results, and the Xperience Reward Program for XEOMIN® for frown lines in adults.

TETRIX® CREAM
http://www.encorederm.com/products/tetrix

Tetrix® Cream is a non-sterile cream formulation intended for prescription use only. Clinical studies provided evidence that Tetrix® Cream prevents nickel salts, neomycin and a mixture of fragrances from making contact with the skin. Please see Clinical Studies section.

VYZULTA (latanoprostene bunod ophthalmic solution)
https://www.vyzulta.com/hcp/

VYZULTA DELIVERS A DUAL MECHANISM OF ACTION. FOR THE REDUCTION OF IOP IN GLAUCOMA Patients1. Vyzulta Banner. One molecule. TWO OUTFLOW PATHWAYS. PROVEN IOP Reduction.1-3*. *In studies up to 12 months' duration, the IOP-lowering effect was up to 7.5 to 9.1 mmHg, in patients with an

Efficacy | ABILIFY MAINTENA (aripiprazole)
https://www.abilifymaintenahcp.com/schizophrenia/efficacy

Examine the efficacy of ABILIFY MAINTENA as demonstrated in 12-week and 52-week studies of adult patients with schizophrenia. See full Safety and Prescribing Information, including BOXED WARNING.

MOXIDECTIN Prescribing Information
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210867lbl.pdf

Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older [see Clinical Studies (14)]. Limitations of Use: Moxidectin Tablets do not kill adult O. volvulus.

GRASTEK® (Timothy Grass Pollen Allergen Extract) Tablet for Sublingual Use
https://www.grastek.com/grastek-healthcare-providers/

Find studies, dosing instructions and the safety and tolerability profile for GRASTEK®. View Safety Info & Boxed Warning.

Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness
https://novartis.gcs-web.com/Novartis-brolucizumab-RTH258-demonstrates-superiority-versus-aflibercept-in-key-secondary-endpoint-measures-of-disease-activity-in-nAMD-a-leading-cause-of-blindness

Nov 9th, 2017 - Novartis, a global leader in ophthalmology, announced further positive results from two Phase III studies of brolucizumab versus aflibercept. Results showed non-inferiority in primary endpoint, superiority in key retinal health outcomes, and long-lasting effect in patients with neovascular age-related macular degeneration (nAMD), a leading cause of blindness. The results of the head-to-head tri...